Other languages MediciNova, Inc.

Equities

MNOV

US58468P2065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
1.35 ^USD	-3.18%		-5.59%	-10.00%

May. 14	MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	CI
May. 09	MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	May. 14
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166	May. 07
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	Mar. 26
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	Mar. 12
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	Jan. 17
Top Premarket Gainers	Jan. 12
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	Dec. 21
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	Dec. 06
Sector Update: Health Care Stocks Lean Down Premarket Monday	Nov. 20
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
MediciNova Secures Patent Notice of Allowance in Canada for Amyotrophic Lateral Sclerosis Combination Treatment	23-10-11
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Canada	23-10-10
MediciNova Says it Received $1 Million Clinical Development Milestone Payment Under Deal With Sanofi Subsidiary	23-10-05
Sector Update: Health Care Stocks Gain Premarket Thursday	23-09-28
MediciNova Says Ibudilast Improved Pulmonary Function in Lung Injury Study	23-09-28
MediciNova, Inc. Announces Results of Studies Under BARDA Contract to Develop MN 166 as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury	23-09-27
MediciNova Announces Abstract Regarding MN-166 in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology	23-08-17
MediciNova Says European Patent Office Issued Notice of Intention to Grant on Macular Injury Therapy Application	23-08-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MediciNova, Inc.

Equities

MNOV

US58468P2065

Other languages

Filters